Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
Open Access
- 12 December 2022
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 10 (12) , e6718
Abstract
This 38‐year‐old man has a familial BRCA2 mutation. He presented with skin erythema, polyarthritis, dactylitis, and febrile erythema nodosum; a biopsy of a liver metastase revealed acinar cell carcinoma of the pancreas. After FOLFIRINOX, olaparib was initiated, and 24 months after, the patient was PS 0 and asymptomatic.Keywords
This publication has 15 references indexed in Scilit:
- Pancreatic cancerThe Lancet, 2020
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerNew England Journal of Medicine, 2019
- Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparibMedicine, 2018
- Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumorsWorld Journal of Gastroenterology, 2017
- Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2017
- Pancreatic Panniculitis and PolyarthritisCurrent Rheumatology Reports, 2017
- Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing RegimenCancer Research and Treatment, 2017
- Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair GenesCancer Discovery, 2014
- Pathology and genetics of pancreatic neoplasms with acinar differentiationSeminars in Diagnostic Pathology, 2014
- Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related TumorsJournal of Clinical Oncology, 2002